MetaCap

Pacific Biosciences of California (PACB) vs Precipio (PRPO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pacific Biosciences of California (PACB) has outperformed Precipio (PRPO) over the past year, losing 26.6% versus a loss of 29.2%. Over five years, PRPO leads with a -54.6% price change compared with -93.0% for PACB. Pacific Biosciences of California is the larger company by market cap ($508.9 million vs $31.1 million), about 16.4 times the size, while Precipio is growing revenue faster (+29.8% vs +3.9%).

Precipio converts more of its revenue into profit, with a net margin of -1.5% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PACB-26.58%PRPO-29.18%
+36%-9%-54%
Nov 21, 20251 yearNov 20, 2026
PACB-93.84%PRPO-55.74%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PACB versus PRPO key metrics
MetricPACBPRPO
Share price$1.63$17.35
Market cap$508.95M$31.11M
1-day change-7.39%-6.17%
YTD return-12.83%-24.50%
1-year return-26.58%-29.18%
5-year return-93.01%-54.58%
Forward P/E—44.49
EPS (TTM)$-0.42$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$160.00M$24.05M
Revenue growth (YoY)+3.89%+29.77%
Net income (latest FY)$-546.38M$-363.00K
Gross margin28.61%44.52%
Operating margin-346.15%-5.00%
Net margin-341.47%-1.51%
52-week high$3.44$33.63
52-week low$1.07$17.30
Distance from 52-week high-52.62%-48.41%
Analyst consensusbuy—
Avg. price target upside+68.10%—
Average volume13.23M79.50K
Shares outstanding312.24M1.79M
Employees48561
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Pacific Biosciences of California is about 16.4 times larger than Precipio by market value ($508.95M vs $31.11M).
  • Precipio is more profitable, keeping -1.5 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
  • Precipio grew revenue faster in its latest fiscal year (+29.77% vs +3.89%).

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

About Precipio

PRPO stock →

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.

Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees

PACB vs PRPO FAQ

Which is bigger, Pacific Biosciences of California or Precipio?

Pacific Biosciences of California (PACB) is larger, with a market capitalization of $508.95M compared with $31.11M for Precipio (PRPO).

Which stock has performed better over the past year, PACB or PRPO?

PACB returned -26.58% over the past 12 months, compared with -29.18% for PRPO (price return, excluding dividends). Past performance does not predict future results.

Are Pacific Biosciences of California and Precipio in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons